



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicants: M. Rigdon Lentz

OCT 10 2003

Serial No.: 09/709,045 ✓

Art Unit: 1647 TECH CENTER 1600/2900

Filed: November 10, 2000

Examiner: J. Seharaseyon

For: *METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449 and copies of the twenty-two (22) documents cited therein.

Enclosed is a check for \$180.00 representing the fee required under 37 C.F.R. §1.17(p) for an Information Disclosure Statement filed after a first Office Action on the merits under 37 C.F.R. §1.97(c). It is believed that no additional fees are required with this submission. However, should an additional fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-1868.

U.S. Patents

10/08/2003 WROCHA1 00000007 09709045

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>01 FC:1806</u>	<u>Class/Subclass</u>	<u>180.00 OP</u>
4,486,282	12-04-1984	Bier		204/180	
5,523,096	09-04-1996	Okarma, et al.		424/489	
5,679,260	10-21-1997	Boos, et al.		210/723	
5,861,483	01-19-1999	Wolpe		530/385	

5,919,898	07-06-1999	Nakatani, et al.	530/345
5,980,887	11-09-1999	Isner, et al.	424/93.7
6,017,527	01-25-2000	Maraskovsky, et al.	424/93.71
6,231,536	05-15-2001	Lentz	604/5.04

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
43 45 200	12-22-1994	Fresenius AG	DE
196 24 250	01-02-1998	Ahrenholz, et al.	DE
WO 91/09967	07-11-1991	Celltech Limited	PCT
WO 01/37873	05-31-2001	Lentz	PCT

Publications

ADERKA, et al., "Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients," *Cancer Res.* 51: 5602-5607 (1991).

AMIT, et al., "Three-dimensional structure of an antigen-antibody complex at 2.8 resolution," *Science* 233: 747-751 (1986).

DIGEL, et al., "High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia," *J. Clin. Invest* 89: 1690-1693 (1992).

ELSÄSSER-BEILE, et al., "Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients," *Tumor Biol.* 15: 17-24 (1993).

KESSLER, "Adsorptive plasma treatment: optimization of extracorporeal devices and systems," *Blood Purif.* 11: 150-157 (1993).

LENTZ, et al., "Low molecular weight protein apheresis and regression of breast cancer," *Jpn. J. Apheresis* 16(1): 107-114 (1997).

PANKA, et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," *Proc. Natl. Acad. Sci. USA* 85: 3080-3084 (1988).

RUDIHOFF, et al., "Single amino acid substitution altering antigen-binding specificity," *Immunology* 79: 1979-1983 (1982).

SELINSKY & HOWELL, "Soluble tumor necrosis factor receptor type I enhances tumor development and persistence *in vivo*," *Cell. Immunol.* 200: 81-87 (2000).


U.S.S.N.: 09/709,045
Filed: November 10, 2000
INFORMATION DISCLOSURE STATEMENT

SELINSKY, "Dissertation: The role of soluble tumor necrosis factor type I in tumor survival," Colorado State University, Fort Collins, Colorado (1999).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.


Respectfully submitted,


Patrea L. Pabst
Reg. No. 31,284

Dated: October 2, 2003

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

U.S.S.N.: 09/709,045
Filed: November 10, 2000
INFORMATION DISCLOSURE STATEMENT



Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: October 2, 2003


Peggy Bailey


1241765_v1

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number	09/709,045
		Filing Date	November 10, 2000
		First Named Inventor	M. Rigdon Lentz
		Group Art Unit	1647
		Examiner Name	J. Seharaseyon
Sheet 2 of 2	Attorney Docket Number	LEN 102	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ADERKA, et al., "Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients," <i>Cancer Res.</i> 51: 5602-5607 (1991).	
		AMIT, et al., "Three-dimensional structure of an antigen-antibody complex at 2.8 resolution," <i>Science</i> 233: 747-751 (1986).	
		DIGEL, et al., "High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia," <i>J. Clin. Invest</i> 89: 1690-1693 (1992).	
		ELSÄSSER-BEILE, et al., "Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients," <i>Tumor Biol.</i> 15: 17-24 (1993).	
		KESSLER, "Adsorptive plasma treatment: optimization of extracorporeal devices and systems," <i>Blood Purif.</i> 11: 150-157 (1993).	
		LENTZ, et al., "Low molecular weight protein apheresis and regression of breast cancer," <i>Jpn. J. Apheresis</i> 16(1): 107-114 (1997).	
		PANKA, et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 85: 3080-3084 (1988).	
		RUDIHOFF, et al., "Single amino acid substitution altering antigen-binding specificity," <i>Immunology</i> 79: 1979-1983 (1982).	
		SELINSKY & HOWELL, "Soluble tumor necrosis factor receptor type I enhances tumor development and persistence <i>in vivo</i> ," <i>Cell. Immunol.</i> 200: 81-87 (2000).	
		SELINSKY, "Dissertation: The role of soluble tumor necrosis factor type I in tumor survival," Colorado State University, Fort Collins, Colorado (1999).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.